BCAB

Bioatla, Inc. (BCAB) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Bioatla, Inc. is a clinical-stage biopharmaceutical company developing conditionally active biologics (CABs) for solid tumor cancers. The company has no approved products and has not generated product revenue. As of the filing date, the company is in a critical financial position, having initiated a formal process to explore strategic options (including asset sales or partnerships) and implemented a workforce reduction of approximately 70% to preserve capital.

Key Financial Metrics

Note: The company reported a significant gain on warrant liability ($2.7 million) and a gain on Pre-Paid Advance (PPA) liability ($0.3 million) which reduced the net loss.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by approximately 47% ($8.3 million) compared to Q1 2025. This was driven primarily by a $7.8 million decrease in Research and Development (R&D) expenses due to the completion of Phase 2 trials for several candidates and the 70% workforce reduction. General and Administrative (G&A) expenses decreased by $0.5 million.
• Liquidity Decline: Cash and cash equivalents dropped from $7.1 million at the end of 2025 to $2.0 million at the end of Q1 2026, representing a net decrease of $5.2 million during the quarter.
• Liability Adjustments: The Pre-Paid Advance (PPA) liability of $4.1 million recorded in late 2025 was fully converted into common stock during Q1 2026, resulting in a $0.3 million gain. The warrant liability decreased from $3.5 million to $0.8 million due to fair value adjustments.
• Share Consolidation: A 50-for-1 share consolidation was approved by stockholders in March 2026 and effected on April 6, 2026. Financial data in this report has been retroactively adjusted to reflect this consolidation.

Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least one year from the issuance date. Current cash ($2.0 million) is insufficient to fund operations for 12 months.
• Strategic Process: The company is actively evaluating strategic options to maximize shareholder value, including the sale of assets, licensing, or partnerships. Clinical development programs, including the Phase 1 trial for BA3182, have been paused or re-evaluated pending the outcome of this process.
• Subsequent Event (Revenue): On May 14, 2026, the company entered into an amendment to its license agreement with Context Therapeutics. Context agreed to pay $6.5 million ($4.5 million immediately and $2.0 million by August 1, 2026) in full satisfaction of all future milestone and royalty obligations. This transaction converts a contingent future revenue stream into a near-term cash inflow.
• Nasdaq Compliance: The company faces risks regarding continued listing on The Nasdaq Capital Market due to previous non-compliance with minimum bid price and stockholders' equity requirements. The share consolidation was intended to address the bid price requirement.

Investor Verification Checklist

• Cash Runway: Verify the timing of the $6.5 million payment from Context Therapeutics and whether it is sufficient to fund operations until a strategic transaction is completed.
• Strategic Transaction Status: Monitor for updates on the formal process to explore strategic options; failure to close a deal could lead to liquidation or bankruptcy.
• Nasdaq Listing Status: Confirm the outcome of the Nasdaq Listing Council review regarding the company's continued listing status.
• Dilution Impact: Review the impact of the 50-for-1 share consolidation and the re-pricing of warrants (exercise price adjusted to $4.35) on existing shareholder equity.
• Restructuring Costs: Confirm that the $0.5 million in restructuring costs recorded in Q1 2026 covers all severance and related liabilities from the 70% workforce reduction.